5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
+15.25%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$484M
AUM Growth
+$484M
(+8.3%)
Cap. Flow
+$15.4M
Cap. Flow
% of AUM
3.19%
Top 10 Holdings %
Top 10 Hldgs %
68.13%
Holding
29
New
1
Increased
3
Reduced
4
Closed
1
Top Buys
| 1 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$36.4M |
| 2 |
EyePoint Pharmaceuticals
EYPT
|
$7.99M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$640K |
| 4 |
Biohaven
BHVN
|
$450K |
Top Sells
| 1 |
Enliven Therapeutics
ELVN
|
$21.9M |
| 2 |
Q32 Bio
QTTB
|
$4.52M |
| 3 |
Cogent Biosciences
COGT
|
$2.47M |
| 4 |
Skye Bioscience
SKYE
|
$1.04M |
| 5 |
Dianthus Therapeutics
DNTH
|
$36.9K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Entrada Therapeutics
TRDA
$208M
| $70.4M | 14.55% | 4,408,379 | – | – |
|
|
2
Enliven Therapeutics
ELVN
$1.2B
| $44.8M | 9.25% | 1,752,174 -858,701 | -33% | -$21.9M |
|
|
3
Skye Bioscience
SKYE
$108M
| $38.8M | 8.01% | 9,913,168 -266,337 | -3% | -$1.04M |
|
|
ARTV
4
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $36.4M | 7.51% | +2,353,304 | New | +$36.4M |
|
|
5
Dianthus Therapeutics
DNTH
$759M
| $33.7M | 6.97% | 1,231,619 -1,346 | -0.1% | -$36.9K |
|
|
6
Biohaven
BHVN
$1.63B
| $23.9M | 4.95% | 478,972 +9,000 | +2% | +$450K |
|
7
Tyra Biosciences
TYRA
$675M
| $22.1M | 4.56% | 939,298 | – | – |
|
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.25B
| $20.5M | 4.25% | 1,285,000 +40,000 | +3% | +$640K |
|
|
TECX
9
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $19.6M | 4.05% | 646,524 | – | – |
|
10
Praxis Precision Medicines
PRAX
$958M
| $19.6M | 4.04% | 340,000 | – | – |
|
11
Celldex Therapeutics
CLDX
$1.47B
| $16.9M | 3.49% | 497,270 | – | – |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $16.8M | 3.46% | 736,595 | – | – |
|
13
Viking Therapeutics
VKTX
$3.04B
| $15M | 3.11% | 237,560 | – | – |
|
14
Pharvaris
PHVS
$1.39B
| $14.8M | 3.05% | 797,600 | – | – |
|
15
Erasca
ERAS
$445M
| $14.8M | 3.05% | 5,405,404 | – | – |
|
16
MoonLake Immunotherapeutics
MLTX
$3.54B
| $14.2M | 2.94% | 282,313 | – | – |
|
17
AnaptysBio
ANAB
$569M
| $12M | 2.48% | 357,733 | – | – |
|
|
SLN
18
Silence Therapeutics
SLN
$227M
| $8.66M | 1.79% | 476,200 | – | – |
|
|
19
EyePoint Pharmaceuticals
EYPT
$797M
| $8.39M | 1.73% | 1,050,000 +1,000,000 | +2,000% | +$7.99M |
|
|
20
Cogent Biosciences
COGT
$1.69B
| $6.07M | 1.25% | 561,854 -228,586 | -29% | -$2.47M |
|
21
scPharmaceuticals
SCPH
$295M
| $5.47M | 1.13% | 1,200,647 | – | – |
|
22
Vor Biopharma
VOR
$250M
| $4.45M | 0.92% | 6,361,723 | – | – |
|
23
Rallybio
RLYB
$22.4M
| $4.25M | 0.88% | 3,630,724 | – | – |
|
24
GH Research
GHRS
$837M
| $3.83M | 0.79% | 572,665 | – | – |
|
25
Adverum Biotechnologies
ADVM
$64.6M
| $3.8M | 0.79% | 541,666 | – | – |
|